Learn how community health presentations are helping people understand that generic drugs are just as safe and effective as brand-name medicines-while saving billions in healthcare costs.
Pharmaceutical prices vary dramatically across countries due to policy differences. The U.S. has high list prices but low generic costs, while countries like Japan and France use negotiation and price caps to keep costs down. Medicare's new negotiation power is changing the landscape.
Generics make up 90% of prescriptions but only 25% of drug spending - yet they drive nearly all pharmacy profits. Here’s how the broken economics of PBMs, spreads, and clawbacks are reshaping who wins and who loses in the drug supply chain.
The FDA approves generic drugs through the ANDA process, ensuring they're as safe and effective as brand-name drugs without repeating costly clinical trials. Learn how bioequivalence, manufacturing standards, and regulatory timelines make generics affordable and reliable.